In Silico Genesis signed up NDA contract (Confidentiality Agreement) with University of Bristol, following initial discussions with faculty members of Centre for Computational Chemistry, School of Chemistry, University of Bristol, England in May/June 2013. This NDA contract was communicated via Research Enterprise Development, on behalf of the Department of Chemistry, for the official signatory of the University of Bristol. This confidentiality agreement bears a specific scope of the permitted purpose, which is relating to research on potential drugs for new medicinal targets for influenza treatments.

We met at e-Infrastructure South Conference and his presentation was of great interest to the work of In Silico Genesis, in the area of the current drug resistance of the existing flu medicines and how it can be alleviated. In order to achieve this, it is necessary to understand what it is causing the resistance at the structural level. His work was spot on, beautifully so.

What was more impressive still, was how the University of Bristol handled the NDA contract, in a most professional and thorough manner. At the time, I was sceptical of anything that was from outside of my Oxford University. They showed me the grace and understanding, instead of walking away from what could have been very unpleasant to them. For that, I am thankful to the University of Bristol, regardless of what may become of this NDA contract in the years to come.

Advertisements